Operational AI to discover your next breakthrough.

Pharma is fragmented by the nature of the regulation itself ,each function (discovery, clinical, safety) owns its own systems and data sources, and compliance rules mean teams legally can’t share more than they’re allowed to, even internally. On top of that, knowledge is heavily dependent on individual people: frequent reorganizations mean that when someone leaves, their knowledge leaves with them, with no structured knowledge transfer to catch it. Closing that gap takes a governed layer that connects what each function already has, without breaking the access boundaries compliance requires ,which is what platforms like Argonos are built to do.

Nothing. Argonos doesn’t replace your ELN, clinical trial systems, or pharmacovigilance databases ,it connects the knowledge trapped inside them so Drug Discovery, Clinical Development, and Pharmacovigilance teams can find what they need faster, with governed access rather than open sharing.

Most of the delay isn’t the science ,it’s reconstructing context that already exists but sits scattered across a fragmented ELN and disconnected literature sources, with no unified view. Unifying that context, under the same compliance-driven access rules each function already operates under, is the fastest lever available before adding new tools or headcount.

The volume problem is real: continuous signal detection now has to run across millions of AE reports from global markets, on top of an already heavy PBRER/PSUR writing burden and the risk of delayed label updates. A missed signal isn’t a minor miss either ,a missed adverse-event report can cost a company millions to billions, which is why scaling detection matters more than adding another point tool.

AI operates on governed data and within defined tasks. Model, prompt, input, output, source, version, and user actions can be monitored and logged. Sensitive actions require human validation, and the underlying workflow remains available without AI so that assistance is reversible rather than operationally mandatory.

Yes. Argonos can be deployed on-premises, in private or hybrid environments, or as controlled SaaS, with granular access governance, approved processing boundaries, lineage, retention controls, and Kubernetes-based scalability.

Argonos is designed for batch, scheduled, interactive, and governed event-driven workflows, including periodic controls, historical analysis, data preparation, rule and model execution, alert generation, case investigation, approvals, and reporting. Near-real-time use cases require an architecture review for latency, resilience, and control requirements. Sub-second payment or card authorization and opaque automated blocking are not the target operating model: Argonos connects detection to explainable investigation and controlled human decision-making.